Terms: = Prostate cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Treatment
50 results:
1. Experience with the US health care system for Black and White patients with advanced prostate cancer.
Rencsok EM; Stopsack KH; Slopen N; Odedina FT; Ragin C; Nowak J; McSwain L; Manarite J; Heath E; George DJ; Kantoff PW; Vinson J; Villanti P; Haneuse S; Mucci LA;
Cancer; 2023 Aug; 129(16):2532-2541. PubMed ID: 37246339
[TBL] [Abstract] [Full Text] [Related]
2. [
Graef J; Bluemel S; Brenner W; Amthauer H; Truckenmueller P; Kaul D; Vajkoczy P; Onken JS; Furth C
J Nucl Med; 2023 Jun; 64(6):892-895. PubMed ID: 37116918
[TBL] [Abstract] [Full Text] [Related]
3. Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.
Roy S; Wallis CJD; Morgan SC; Kishan AU; Le ATT; Malone J; Sun Y; Spratt DE; Saad F; Malone S
Prostate; 2023 Jul; 83(10):912-921. PubMed ID: 37071764
[TBL] [Abstract] [Full Text] [Related]
4. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract] [Full Text] [Related]
5. Identification of the Key Genes Involved in the Tumorigenesis and Prognosis of prostate cancer.
Wang W; Wu Q; Mohyeddin A; Liu Y; Liu Z; Ge J; Zhang B; Shi G; Wang W; Wu D; Wang F
Comput Math Methods Med; 2022; 2022():5500416. PubMed ID: 36245843
[TBL] [Abstract] [Full Text] [Related]
6. Socioeconomic differences in prostate cancer treatment: A systematic review and meta-analysis.
Gallagher BDT; Coughlin EC; Nair-Shalliker V; McCaffery K; Smith DP
Cancer Epidemiol; 2022 Aug; 79():102164. PubMed ID: 35526516
[TBL] [Abstract] [Full Text] [Related]
7. Environmental Phenol and Paraben Exposure Risks and Their Potential Influence on the Gene Expression Involved in the Prognosis of prostate cancer.
Alwadi D; Felty Q; Roy D; Yoo C; Deoraj A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409038
[TBL] [Abstract] [Full Text] [Related]
8. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract] [Full Text] [Related]
9. Carbon Ion Radiotherapy Evokes a Metabolic Reprogramming and Individualized Response in prostate cancer.
Ning R; Pei Y; Li P; Hu W; Deng Y; Hong Z; Sun Y; Zhang Q; Guo X
Front Public Health; 2021; 9():777160. PubMed ID: 34950631
[No Abstract] [Full Text] [Related]
10. Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real-world evidence study.
Liu JM; Wu CT; Hsu RJ; Hsu WL
Cancer Med; 2021 Nov; 10(22):8162-8171. PubMed ID: 34590436
[TBL] [Abstract] [Full Text] [Related]
11. Gene Expression Analysis Reveals Key Genes and Signalings Associated with the Prognosis of prostate cancer.
Shen H; Guo YL; Li GH; Zhao W; Zhang L
Comput Math Methods Med; 2021; 2021():9946015. PubMed ID: 34497666
[TBL] [Abstract] [Full Text] [Related]
12. Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
Rosenberg JE; Jung JH; Lee H; Lee S; Bakker CJ; Dahm P
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013677. PubMed ID: 34365635
[TBL] [Abstract] [Full Text] [Related]
13. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract] [Full Text] [Related]
14. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract] [Full Text] [Related]
15. Influence of sociodemographic factors on treatment's choice for localized prostate cancer in Portugal.
Pereira-Lourenço M; Vieira E Brito D; Peralta JP; Godinho R; Conceiçao P; Reis M; Rabaça C; Sismeiro A
Arch Ital Urol Androl; 2020 Apr; 92(1):45-49. PubMed ID: 32255317
[TBL] [Abstract] [Full Text] [Related]
16. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical prostatectomy.
Martini A; Marqueen KE; Falagario UG; Waingankar N; Wajswol E; Khan F; Fossati N; Briganti A; Montorsi F; Tewari AK; Stock R; Rastinehad AR
JAMA Netw Open; 2020 Mar; 3(3):e201913. PubMed ID: 32232450
[TBL] [Abstract] [Full Text] [Related]
17. Other- and all-cause Mortality among women with breast cancer.
Pierre-Victor D; Pinsky PF; McCaskill-Stevens W
Cancer Epidemiol; 2020 Apr; 65():101694. PubMed ID: 32135504
[TBL] [Abstract] [Full Text] [Related]
18. Radical prostatectomy or Observation for Clinically Localized prostate cancer: Extended Follow-up of the prostate cancer Intervention Versus Observation Trial (PIVOT).
Wilt TJ; Vo TN; Langsetmo L; Dahm P; Wheeler T; Aronson WJ; Cooperberg MR; Taylor BC; Brawer MK
Eur Urol; 2020 Jun; 77(6):713-724. PubMed ID: 32089359
[TBL] [Abstract] [Full Text] [Related]
19. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer.
Wong RL; Duong MT; Tangen CM; Agarwal N; Cheng HH; Vogelzang NJ; Hussain M; Thompson IM; Quinn DI; Yu EY
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):486-493. PubMed ID: 32055002
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Association of prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant prostate cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
[TBL] [Abstract] [Full Text] [Related]
[Next]
